ANKRD11 deficiency reprograms CD8(+) T cell differentiation to enhance immunity in chronic infection and cancer.

ANKRD11 deficiency in CD8+ T cells enhances antiviral and antitumor immunity by promoting effector differentiation and function in chronic infection and cancer.

• Why it matters: CD8+ T cell dysfunction impairs clearance of hepatitis B virus and antitumor responses, creating a need for strategies to restore T cell activity in these conditions.
• What they did: Using a humanized mouse model, the study knocked out Ankrd11 in CD8+ T cells, revealing increased proliferation, effector differentiation, and reprogramming of exhausted T cells, especially under immunosuppressive conditions.
• The result: Ankrd11-deficient T cells exhibit higher granzyme levels and improved effector functions, leading to better viral control and tumor regression, highlighting ANKRD11 as a potential immunotherapy target.